BQ123
PreclinicalSmall molecule
BQ123 is one of 44 small molecule programs targeting Vasculitis. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
171 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1NOVOLIN R
Novo NordiskPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Routine Treatment
GSKPreclinical
Sulfonylureas
Eli LillyPreclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Antiplatelet Drug
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preclinical
Lovaza
AstraZenecaPreclinical
Insulins
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BQ123. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- VVanderbilt University